Senate Majority Leader Chuck Schumer Announces Updates to Bill to Federally Legalize Cannabis
In February, Senate Majority Leader Chuck Schumer explained in a press conference and in a letter to colleagues the details of his bill to federally legalize cannabis and announced his plan to introduce it in the coming weeks.
Senate Majority Leader Chuck Schumer announced his plans to file a bill in April 2022 to federally legalize cannabis (1,2). He also said in a letter to colleagues that he and other senators have already received comments on the draft from a broad array of relevant sources and are requesting input from leaders of relevant committees and from senators who have dealt with legalization in their own states.
Schumer first disclosed details about his Cannabis Administration & Opportunity Act (CAOA), which he unveiled in draft form for public comment in July 2021, and he expects committee hearings on the proposal shortly after it’s formally filed.
“One major hurdle continues to stand in the way of states’ ability to make their own decisions about cannabis—the continued prohibition of marijuana at the federal level,” said Schumer. “As more and more states move to legalize cannabis for both adult and medical use, the federal government has an important role to play. Hundreds of millions of Americans live in states that have legalized cannabis in some form while it remains illegal at the federal level.”
The proposal would federally deschedule cannabis, expunge prior convictions, allow people to petition for resentencing, maintain the authority of states to set their own cannabis policies, and remove collateral consequences such as immigration-related penalties for people who’ve been criminalized over the plant.
The bill would also impose a federal tax on cannabis products and direct some of that revenue to grant programs meant to support people from communities most impacted by the prohibition who want to participate in the industry. It would transfer regulatory authority over cannabis from the US Drug Enforcement Administration (DEA) to the Food and Drug Administration (FDA), the Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), and the Alcohol and Tobacco Tax and Trade Bureau (TTB).
References
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
